These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 11796990)
41. Nucleic acid-based vaccines as an approach to immunization against human immunodeficiency virus type-1. Bagarazzi ML; Boyer JD; Ayyavoo V; Weiner DB Curr Top Microbiol Immunol; 1998; 226():107-43. PubMed ID: 9479839 [No Abstract] [Full Text] [Related]
42. Targeting HIV reservoirs and reconstituting the immune system. Second annual meeting Research Institute for Genetic and Human Therapy April 18-19, 1999 Washington, DC. Lori F; Lisziewicz J AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1597-617. PubMed ID: 10606083 [No Abstract] [Full Text] [Related]
43. HIV escape from cytotoxic T lymphocytes: a potential hurdle for vaccines? Barouch DH; Letvin NL Lancet; 2004 Jul 3-9; 364(9428):10-1. PubMed ID: 15234837 [No Abstract] [Full Text] [Related]
44. [Status and current strategies of HIV vaccine development]. Wild J; Wagner R Internist (Berl); 2003 Jun; 44(6):711-8. PubMed ID: 14567107 [TBL] [Abstract][Full Text] [Related]
45. Human immunodeficiency virus type 1 vaccine development: recent advances in the cytotoxic T-lymphocyte platform "spotty business". Schoenly KA; Weiner DB J Virol; 2008 Apr; 82(7):3166-80. PubMed ID: 17989174 [No Abstract] [Full Text] [Related]
46. Development of multicomponent DNA vaccination strategies against HIV. Kim JJ; Weiner DB Curr Opin Mol Ther; 1999 Feb; 1(1):43-9. PubMed ID: 11249683 [No Abstract] [Full Text] [Related]
47. Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, May 21, 2015. Weniger BG; Anglin IE; Tong T; Pensiero M; Pullen JK; Vaccine; 2018 Jan; 36(4):427-437. PubMed ID: 29174315 [TBL] [Abstract][Full Text] [Related]
48. Retracing our STEP towards a successful CTL-based HIV-1 vaccine. Yang OO Vaccine; 2008 Jun; 26(25):3138-41. PubMed ID: 18339458 [No Abstract] [Full Text] [Related]
49. HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. McElrath MJ; Siliciano RF; Weinhold KJ AIDS Res Hum Retroviruses; 1997 Feb; 13(3):211-6. PubMed ID: 9115806 [No Abstract] [Full Text] [Related]
50. Genetic influences on HIV infection: implications for vaccine development. Smith MZ; Kent SJ Sex Health; 2005; 2(2):53-62. PubMed ID: 16335742 [TBL] [Abstract][Full Text] [Related]
51. Cytokine profiles in HIV type 1 disease and protection. Shearer GM; Clerici M AIDS Res Hum Retroviruses; 1998 Jun; 14 Suppl 2():S149-52. PubMed ID: 9672232 [No Abstract] [Full Text] [Related]
54. The HIV/AIDS vaccine research effort: an update. Beyrer C Hopkins HIV Rep; 2003 Jan; 15(1):6-7. PubMed ID: 12542004 [No Abstract] [Full Text] [Related]
55. Preparing for HIV vaccines that induce cytotoxic T lymphocytes. McMichael A Curr Opin Immunol; 1998 Aug; 10(4):379-81. PubMed ID: 9722911 [No Abstract] [Full Text] [Related]
56. One-two combination. von Bubnoff A IAVI Rep; 2007; 11(3):11-4. PubMed ID: 20210046 [No Abstract] [Full Text] [Related]
59. Minor nef gene alterations after human HIV-DNA immunisation. Aleman S; Leitner T; Liu MA; Wahren B AIDS; 2004 Mar; 18(5):817-9. PubMed ID: 15075520 [No Abstract] [Full Text] [Related]
60. Could a nasal spray protect people against human immunodeficiency virus? Bull World Health Organ; 1999; 77(12):1017-8. PubMed ID: 10712065 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]